AZD3463 ALK/IGF1R Inhibitor: Targeted Neuroblastoma Pathway Modulation

Executive Summary. AZD3463 is an orally available small molecule that potently inhibits both anaplastic lymphoma kinase (ALK) and insulin-like growth factor 1 receptor (IGF1R) with a Ki of 0.75 nM, showing high selectivity and efficacy in neuroblastoma models (ApexBio). It blocks ALK-mediated PI3K/AKT/mTOR signaling, leading to dose-dependent induction of apoptosis and autophagy in vitro and significant tumor growth reduction in vivo (Labrèche et al. 2021). AZD3463 overcomes resistance caused by ALK activating mutations (e.g., F1174L, D1091N), outperforms first-generation inhibitors in mutant backgrounds, and synergizes with chemotherapeutics such as doxorubicin and temozolomide. The compound is insoluble in water and ethanol but dissolves in DMSO at ≥11.22 mg/mL, providing flexible workflow compatibility. AZD3463 is a leading candidate for translational neuroblastoma research and multi-pathway resistance studies.

Biological Rationale

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase predominantly expressed in neuronal tissues. In neuroblastoma, ALK is frequently upregulated or mutated, driving tumor cell proliferation and survival. Activating mutations, such as F1174L and D1091N, enhance ALK signaling and confer resistance to first-line ALK inhibitors. The PI3K/AKT/mTOR pathway is a critical downstream effector of ALK, tightly regulating cell survival and growth. IGF1R, another receptor tyrosine kinase, further amplifies PI3K/AKT/mTOR signaling, contributing to oncogenic crosstalk and therapy resistance (Labrèche et al. 2021). Targeting both ALK and IGF1R is therefore a rational strategy for disrupting redundant survival pathways in neuroblastoma and overcoming resistance mechanisms.

Mechanism of Action of AZD3463 ALK/IGF1R Inhibitor

AZD3463 is a small molecule inhibitor with dual activity against ALK and IGF1R. It binds with high affinity (Ki = 0.75 nM), selectively inhibiting kinase activity and downstream signaling. In neuroblastoma cells, AZD3463 blocks ALK-mediated activation of the PI3K/AKT/mTOR pathway, leading to reduced phosphorylation of AKT and mTOR. This results in suppression of cell proliferation, induction of apoptosis, and stimulation of autophagy. The inhibitor is effective against wild-type ALK and common activating mutations F1174L and D1091N, including those conferring resistance to crizotinib and other first-generation ALK inhibitors (AZD3463 ALK/IGF1R inhibitor). By also targeting IGF1R, AZD3463 disrupts compensatory survival signals, further enhancing its cytotoxic impact in neuroblastoma models.

Evidence & Benchmarks

• AZD3463 inhibits ALK kinase activity with a Ki of 0.75 nM under standard in vitro assay conditions (product page).
• In neuroblastoma cell lines (both wild-type and ALK mutants), AZD3463 reduces cell proliferation in a dose-dependent manner at concentrations from 5 to 50 μM (DMSO vehicle, 37°C, 5% CO₂) (ApexBio).
• Combining AZD3463 with doxorubicin or temozolomide achieves synergistic cytotoxicity, with enhanced apoptosis rates compared to monotherapy (in vitro, 24–72 h exposure) (product documentation).
• AZD3463, administered intraperitoneally at 15 mg/kg daily for two days, significantly reduced tumor volume in orthotopic neuroblastoma xenograft mouse models (immunodeficient mice, n ≥ 5 per group) (ApexBio).
• ALK-driven PI3K/AKT/mTOR signaling is a validated therapeutic target in neuroblastoma and other cancers, as demonstrated by pathway cross-talk studies (Labrèche et al. 2021).

Applications, Limits & Misconceptions

AZD3463 is primarily indicated for preclinical research in neuroblastoma and other ALK-driven malignancies. Its dual inhibition profile makes it suitable for studies of pathway crosstalk and resistance mechanisms. The compound is also valuable in combination therapy models, especially for overcoming resistance to first-generation ALK inhibitors.

For a deep-dive into translational strategies, see AZD3463 ALK/IGF1R Inhibitor: Unraveling Multi-Pathway Con..., which details crosstalk and translational applications; the current article updates this with new in vivo benchmarks and workflow guidance. For stepwise protocols, AZD3463 ALK/IGF1R Inhibitor: Applied Workflows in Neurobl... focuses on troubleshooting and experiment design, whereas our review emphasizes comparative evidence and mechanistic rationale. For a broader view of resistance reversal, see AZD3463 ALK/IGF1R Inhibitor: Transforming Neuroblastoma R..., which we extend by detailing quantitative efficacy and storage parameters.

Common Pitfalls or Misconceptions

• AZD3463 is not water or ethanol soluble; improper solvent use reduces efficacy.
• Long-term storage of prepared DMSO solutions (>several months) is not recommended due to potential compound degradation.
• The inhibitor is not validated for clinical use; all data are preclinical and for research purposes only.
• AZD3463 may not fully overcome resistance in ALK-independent tumor escape variants.
• Synergy with chemotherapeutics may vary by cell line and tumor context; optimization is required for each model.

Workflow Integration & Parameters

AZD3463 is a solid compound with a molecular weight of 448.95 g/mol and formula C₂₄H₂₅ClN₆O. It is insoluble in water and ethanol but dissolves in DMSO at ≥11.22 mg/mL. For optimal solubility, stock solutions should be prepared in DMSO, optionally warmed or sonicated, and stored at -20°C for short to moderate durations (up to several months). For cell-based assays, working concentrations range from 5–50 μM, with exposure times of 24–72 hours. In vivo, AZD3463 is typically administered intraperitoneally at 15 mg/kg daily in appropriate animal models.

For more on experiment design, troubleshooting, and protocol optimization, refer to the workflow guide AZD3463 ALK/IGF1R Inhibitor: Applied Workflows in Neurobl.... The current article compiles updated solubility and handling data and benchmarks efficacy in clinically relevant models.

Conclusion & Outlook

AZD3463 is a next-generation research tool for dissecting ALK/IGF1R-driven oncogenic signaling in neuroblastoma and related cancers. Its high potency, mutation coverage, and synergy with standard chemotherapeutics make it a robust platform for preclinical studies. Ongoing research aims to clarify its utility in additional ALK-driven malignancies and refine dosing protocols for maximum translational impact. For current product specifications and ordering, see the AZD3463 ALK/IGF1R inhibitor product page.